10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abnormal development can lead to deficits in adult brain function, a trajectory likely underlying adolescent-onset psychiatric conditions such as schizophrenia. Developmental manipulations yielding adult deficits in rodents provide an opportunity to explore mechanisms involved in a delayed emergence of anomalies driven by developmental alterations. Here we assessed whether oxidative stress during presymptomatic stages causes adult anomalies in rats with a neonatal ventral hippocampal lesion, a developmental rodent model useful for schizophrenia research. Juvenile and adolescent treatment with the antioxidant N-acetyl cysteine prevented the reduction of prefrontal parvalbumin interneuron activity observed in this model, as well as electrophysiological and behavioral deficits relevant to schizophrenia. Adolescent treatment with the glutathione peroxidase mimic ebselen also reversed behavioral deficits in this animal model. These findings suggest that presymptomatic oxidative stress yields abnormal adult brain function in a developmentally compromised brain, and highlight redox modulation as a potential target for early intervention.

          Related collections

          Author and article information

          Journal
          Neuron
          Neuron
          1097-4199
          0896-6273
          Sep 3 2014
          : 83
          : 5
          Affiliations
          [1 ] Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.
          [2 ] Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
          [3 ] Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
          [4 ] Sound Pharmaceuticals, Inc, Research and Development, Seattle, WA, USA.
          [5 ] Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; Maryland Psychiatric Research Center, Baltimore, MD, USA.
          [6 ] Centre for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland. Electronic address: kim.do@chuv.ch.
          [7 ] Program in Neuroscience, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: patricio.odonnell@pfizer.com.
          Article
          S0896-6273(14)00639-4 NIHMS618023
          10.1016/j.neuron.2014.07.028
          25132466
          67b5f7e7-7360-49c7-9aa2-1d40890e7a17
          Copyright © 2014 Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article